Recent News

ASCO 2022: Study Sheds Light on Richter’s Syndrome in Patients With CLL

ASCO 2022: How Informed Are Patients With CLL in North America and the European Union?

ASCO 2022: Novel BCL2 Inhibitor Under Study in Treatment of Resistant CLL

ASCO 2022: Racial/Ethnic Identity and Overall Survival for Patients With CLL

ASCO 2022: Extended Follow-up With Obinutuzumab, Ibrutinib, and Venetoclax in CLL

ASCO 2022: 3-Year Follow-up on Fixed-Duration Ibrutinib/Venetoclax in First-Line Setting in CLL

MicroRNA Modulation of the TGF-β Pathway in CLL: Novel Molecular Connection?

Focal Adhesion Kinase: Potential Therapeutic Target in CLL?

Lisocabtagene Maraleucel CAR T-Cell Therapy in Patients With CLL

Response to Shingles Vaccine Among Patients Treated With BTK Inhibitors for CLL

How Effective Is COVID-19 Vaccination in Patients With CLL?

Addition of Novel BTK Inhibitor Pirtobrutinib to Combination Therapy May Improve Resistant CLL

AACR 2022: Fixed-Duration Regimen of Ibrutinib/Venetoclax for CLL With High-Risk Features

AACR 2022: ATR Inhibitor Alone or With BTK Inhibitor in High-Risk Resistant CLL

AACR 2022: MEK Inhibition as Potential Alternative Therapy for Patients With CLL

AACR 2022: Is Loss of the AID Enzyme Linked to Progression of CLL?

AACR 2022: PI3Kδ Inhibitor Zandelisib Under Study in CLL

Newly Developed Health-Related Quality-of-Life Questionnaire for CLL Treatment Decision-Making

Adding EP4 Receptor Agonists to CD20 Antigen Therapy in B-Cell Malignancies

Prognostic Value of Epigenetic Classification System in Patients With CLL

Is the CLL Comorbidity Index a Prognostic Tool in Research and Clinical Practice?

CD105 Expression: A Potential Risk Marker in CLL?

Can Olive Phenols Benefit Patients With CLL?

Chromosomal Microarray Analysis: Prognostic for Patients With Richter Transformation?

FDA Brief: Supplemental New Drug Application Accepted for Zanubrutinib in CLL

COVID-19 Vaccination Effectiveness in Patients With CLL: Focus on Humoral Response

Exploring the Combination of PD-1 and CDK9 Inhibitors in Hematologic Cancers

Does Interleukin 9 Play a Role in the Pathogenesis of CLL?

Novel BTK Inhibitor Alone or in Combination With Ublituximab and Umbralisib in CLL

Ibrutinib-Based Initial Therapy for Younger, Fit Patients With CLL

Initial Results of French Trial of Ibrutinib Plus Venetoclax in Intermediate-Risk CLL

Time-Limited Venetoclax-Based Combination Therapies for CLL

In Memoriam: Remembering Hematologist Steve E. Coutre, MD

Updated Phase I/II BRUIN Study of Next-Generation BTK Inhibitor Pirtobrutinib in CLL

SEQUOIA Update on Zanubrutinib Versus Bendamustine Plus Rituximab in CLL

Preclinical Findings With Novel CDK9 Inhibitor in CLL